Group 1 - The company, Sely Medical, announced that its controlling shareholder, Saihai Technology, has completed the process of releasing the pledge on 6 million shares and subsequently pledged 5 million shares to Shanghai Zhangjiang Technology Microfinance Co., Ltd [1] - Saihai Technology holds approximately 21.64 million unrestricted circulating shares, accounting for 10.3% of the company's total share capital. After the recent transactions, the total pledged shares amount to 16 million, representing 73.93% of Saihai's holdings and 7.61% of the total share capital [1] - The actual controller, Mr. Wen Wei, holds about 9.63 million shares, which is 4.58% of the total share capital. He has pledged 5.3 million shares, accounting for 55.01% of his holdings and 2.52% of the total share capital [1] Group 2 - As of the announcement date, the total pledged shares by both Saihai Technology and Mr. Wen Wei amount to 21.3 million, which is 68.1% of their combined holdings and 10.14% of the total share capital [1] - For the fiscal year 2024, the company's revenue composition is projected to be 97.09% from commercial activities and 2.91% from industrial activities [1] - The current market capitalization of Sely Medical is 6.7 billion yuan [2]

| 证券简称：塞力医疗 | 公告编号：2025-080 | | --- | --- | | 债券简称：塞力转债 | | | 证券代码：603716 债券代码：113601 | | 塞力斯医疗科技集团股份有限公司 关于控股股东部分股份解除质押及股份质押的公告 公司近日收到控股股东赛海科技的通知，赛海科技将前期质押给海南润泰欣 茂小额贷款有限公司的 6,000,000 股股份办理了解除质押登记手续，后将 5,000,000 股股份办理了股份质押登记手续，质权人为上海张江科技小额贷款股 份有限公司。现将有关情况说明如下： （一）本次部分股份解除质押情况 | 股东 | 是否为控 | 本次质押 | 是否为 | 是否补 | 质押起始 | | 质押到 | 质权人 | 占其所 持股份 | 占公司 总股本 | 质押融资 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 股股东 | 股数（股） | 限售股 | 充质押 | 日 | | 期日 | | | | 资金用途 | | | | | | | | | | | 比例 ...

Market Overview - The pharmaceutical commercial sector increased by 0.19% on September 16, with Saily Medical leading the gains [1] - The Shanghai Composite Index closed at 3861.87, up 0.04%, while the Shenzhen Component Index closed at 13063.97, up 0.45% [1] Top Gainers - Saily Medical (603716) closed at 31.80, up 5.75% with a trading volume of 461,500 shares and a transaction value of 1.457 billion [1] - First Pharmaceutical (600833) closed at 14.33, up 3.47% with a trading volume of 159,400 shares and a transaction value of 229 million [1] - Ruikang Pharmaceutical (002589) closed at 3.05, up 2.35% with a trading volume of 564,800 shares and a transaction value of 170 million [1] Other Notable Stocks - Haiwang Biological (000078) closed at 2.72, up 1.87% with a trading volume of 472,600 shares and a transaction value of 128 million [1] - Yiyigou (300937) closed at 28.06, up 1.41% with a trading volume of 13,100 shares and a transaction value of 36.54 million [1] Market Capital Flow - The pharmaceutical commercial sector saw a net inflow of 1.0663 million from institutional investors, while retail investors had a net inflow of 3.2772 million [2] - However, speculative funds experienced a net outflow of 33.8383 million [2] Individual Stock Capital Flow - Saily Medical had a net inflow of 99.8444 million from institutional investors, while it faced a net outflow of 39.1679 million from speculative funds [3] - First Pharmaceutical saw a net inflow of 21.4721 million from institutional investors, but a net outflow of 2.02355 million from retail investors [3] - Ruikang Pharmaceutical had a net inflow of 8.2730 million from institutional investors, with a slight net outflow from speculative funds [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603716 证券简称：塞力医疗 公告编号：2025-078 塞力斯医疗科技集团股份有限公司 2025年第四次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东大会召开的时间：2025年9月15日 (二)股东大会召开的地点：公司（武汉市东西湖区金山大道1310号）A栋A会议室 2、公司在任监事3人，出席3人； 3、董事会秘书范莉女士出席本次会议；其他高管列席本次会议。 二、议案审议情况 (一)非累积投票议案 1、议案名称：关于取消监事会、变更公司注册资本并修订《公司章程》的议案 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： ■ (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由塞力斯医疗科技集团股份有限公司董事会召集，由公司董事长温伟先生主持。本次会议 的召集、召开、表决方式符合有关法律、行政法规、部门规章和 ...

证券日报网讯 9月15日晚间，塞力医疗发布公告称，公司于2025年9月15日召开2025年第一次职工代表 大会，选举鲁翌先生担任公司第五届董事会职工董事，任期自公司2025年第一次职工代表大会选举通过 之日起至第五届董事会任期届满之日止。 （编辑 任世碧） ...

| 证券简称：塞力医疗 | 公告编号：2025-079 | | --- | --- | | 债券简称：塞力转债 | | | 证券代码：603716 债券代码：113601 | | 选举鲁翌先生担任公司第五届董事会职工董事，任期自公司 2025 年第一次 职工代表大会选举通过之日起至第五届董事会任期届满之日止。鲁翌先生将与公 司2024年第三次临时股东大会选举产生的8名董事共同组成公司第五届董事会。 届时，公司第五届董事会成员将由原来的 8 人调整为 9 人。 塞力斯医疗科技集团股份有限公司 本次职工董事选举产生后，公司第五届董事会中兼任公司高级管理人员职 务的董事以及由职工代表担任的董事人数，总计未超过公司董事总数的二分之一， 符合有关法律法规、规范性文件及《公司章程》的规定。 关于选举职工董事的公告 鲁翌先生简历详见附件。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 特此公告。 根据《公司法》等法律法规、规范性文件及《公司章程》的有关规定，塞力 斯医疗科技集团股份有限公司（以下简称"公司"或"本公司"）于 2025 年 ...

重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 9 月 15 日 (二)股东大会召开的地点：公司（武汉市东西湖区金山大道 1310 号）A 栋 A 会议 室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 789 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 43,839,503 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 21.2618 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 证券代码：603716 证券简称：塞力医疗 公告编号：2025-078 塞力斯医疗科技集团股份有限公司 2025年第四次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本次股东大会由塞力斯医疗科技集团股份有限公司董事会召集，由公司董事 长温伟先生主持。本次会议的召集、召开、表决方 ...

国浩律师（上海）事务所 国浩律师（上海）事务所 之 法律意见书 上海市静安区山西北路 99 号苏河湾中心 25-28 楼 邮编：200085 25-28th Floor, Suhe Centre, No.99 West Shanxi Road, Shanghai 200085, China 电话/Tel:+86 21 5234 1668 传真/Fax:+86 21 5243 3320 网址/Website: http://www.grandall.com.cn 2025 年 9 月 国浩律师（上海）事务所 法律意见书 关 于 塞力斯医疗科技集团股份有限公司 2025 年第四次临时股东大会 关于塞力斯医疗科技集团股份有限公司 2025 年第四次临时股东大会之法律意见书 致：塞力斯医疗科技集团股份有限公司 塞力斯医疗科技集团股份有限公司（以下简称"公司"）2025 年第四次临 时股东大会于 2025 年 9 月 15 日召开。国浩律师（上海）事务所（以下简称 "本所"）经公司聘请，委派律师出席现场会议，见证公司 2025 年第四次临时 股东大会（以下简称"本次股东大会"）。 本所律师根据《中华人民共和国公司法》《 ...

Market Overview - The pharmaceutical commercial sector experienced a slight decline of 0.14% on September 15, with Saily Medical leading the drop [1] - The Shanghai Composite Index closed at 3860.5, down 0.26%, while the Shenzhen Component Index rose by 0.63% to 13005.77 [1] Stock Performance - Notable gainers in the pharmaceutical sector included Baiyang Pharmaceutical, which rose by 1.37% to a closing price of 31.06, and HeFu China, which increased by 1.04% to 6.80 [1] - Saily Medical saw a significant decline of 3.96%, closing at 30.07, with a trading volume of 423,500 shares and a transaction value of 1.287 billion [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 338 million from major funds, while retail investors contributed a net inflow of 265 million [2][3] - The stock with the highest net inflow from major funds was Yifeng Pharmacy, with 25.68 million, while it faced a net outflow of 21.63 million from retail investors [3]

Core Viewpoint - The announcement details the pledge of shares by the controlling shareholder of Saily Medical Technology Group Co., Ltd., indicating a significant portion of shares has been pledged, but the company maintains that this will not affect its operations or control [2][5][6]. Group 1: Share Pledge Details - The controlling shareholder, Saihai (Shanghai) Health Technology Co., Ltd., holds 21,642,540 shares, representing 10.30% of the total share capital, and has pledged 3,000,000 shares recently [2]. - After the recent pledge, Saihai Technology has a total of 17,000,000 pledged shares, which is 78.55% of its holdings and 8.09% of the total share capital [2]. - The actual controller, Mr. Wen Wei, holds 9,634,208 shares (4.58% of total share capital) and has pledged 5,300,000 shares, which is 55.01% of his holdings [2]. Group 2: Future Pledge and Financing - Within the next six months, 6,000,000 shares are set to mature, accounting for 19.18% of their holdings and 2.86% of total share capital, with a corresponding financing balance of 14.61 million yuan [5]. - In the next year, an additional 9,000,000 shares will mature, representing 28.78% of their holdings and 4.28% of total share capital, with a financing balance of 36 million yuan [5]. - The funds from the recent pledge are primarily intended to repay previous pledge financing debts, and the company asserts that it has the ability to repay these debts [5][6]. Group 3: Risk Management and Impact - The company states that the pledge will not impact its operations, main business, financing costs, or ongoing viability, and there is no risk of a change in actual control [6]. - The credit status of Saihai Technology and Mr. Wen Wei is reported to be good, with manageable pledge risks, and they are prepared to take measures if stock prices approach warning or liquidation levels [6].